Nectar Lifescience Ltd Company History

Nectar Lifesciences Ltd has appointed Mr. Basant Kumar Goswami, I.A.S. (retd.) on the Board as an additional director (Independent director) of the Company who shall hold the office upto the date of next Annual General Meeting.

The Company has splits its face value from Rs10/- to Rs1/-.

The company has recommended the Final Dividend of Re. 0.10 per equity share.

Nectar Lifesciences elevates to the rank of 365 in the list of India's top companies

The Company have declared the interim dividend of Re. 0.25/- per equity share.

NecLife granted 'Certificate of Suitability' for Cefuroxime Axetil in European Union

NecLife announces the receipt of Japanese MOH approval for Cefuroxime Axetil

NecLife announces the receipt of South Africa 'MCC' approval for Ceftriaxone.

The Company has recommended 10% Final Dividend i.e. Re. 0.10/- per equity share

European cGMP Approval for NecLife's Cephalosporin Formulation Facility

NecLife granted 'Certificate of Suitability' for Cefuroxime Sodium (Sterile) in European Union".

The Company recommendation of 10% Final Dividend i.e. Re 0.10/- per equity share.

The Company has appointed Mr. Harparkash Singh Gill on the Board as Wholetime Director [designated as President (Operation) & Director.

Nectar Lifesciences Ltd has appointed Mr. Dinesh Dua as an Additional Director as well as Wholetime Director (designated as Chief Executive Officer) of the company.

Mr. Sanjiv Goyal, CMD, Nectar Lifesciences Ltd., Chandigarh gets coveted Outstanding Entrepreneurship of the Year from Asia Pacific Enterprise Awards(APEA)".

NecLife gets European cGMP Approval for its Orals & Injectables Cephalsporins FDF Facility.

Nectar Lifesciences Ltd. honoured with NECA 2015 Award

.

Nectar Biopharma launches generic diabetes treatment drug in India.